Merck funds ARVS, Moeti applauds! :: Mmegi Online

Managing director of African Comprehensive HIV/AIDS Partnerships (ACHAP), Dr Themba Moeti, has commended drug maker Merck & Co. Inc on its second phase of funding and donations of Anti Retroviral (ARV) towards addressing the needs of people living with HIV/AIDS in the country.

Moeti registered the compliment last week following an announcement that drug maker, Merck & Co. Inc, and the Bill & Melinda Gates Foundation will commit an additional $60 million to ACHAP. With Tuesday's pledge, the Merck Foundation and the Gates Foundation's total cash contributions now amount to $166.5 million.

"Our partners' contributions, through funding, antiretroviral drugs medicine donations and medical expertise, have been absolutely essential to our ability to address the needs of Batswana living with HIV and AIDS," said Moeti.He added that they look forward to strengthening the partnership as it enters the second phase.

Already have an active account? Log in here.

Or Sign up and get unlimited access to premium articles.

Explore

More

Merck funds ARVS, Moeti applauds!

Managing director of African Comprehensive HIV/AIDS Partnerships (ACHAP), Dr Themba Moeti, has commended drug maker Merck & Co. Inc on its second phase of funding and donations of Anti Retroviral (ARV) towards addressing the needs of people living with HIV/AIDS in the country.

Civil Society fights 'flawed' constitutional amendment

Civil Society calls for Constitution review governing Act

IEC rejects 2,513 registrations

Motshegwa prevails against detractors

Serowe woman ingests acid, attempts suicide

Serowe man 'loses' P1m in crypto trading

MultiChoice appoints Johnson Otlaadisa to the role of Production Supervisor for Mzansi Bioskop Local Film Project

Grieving individuals urged to seek support

Inspect the voters' roll!